Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)-Reply

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)-Reply In Reply. —Regarding the comments by Dr Kaufman on the ultrasound data, the ultrasound instrument used in MIDAS was Biosound 2000 II spectrum analysis with 8-MHz annular arrays (approximate axial resolution, 0.3 mm). This was defined in the original protocol and previously published.1 Kaufman notes that the intimal-medial thickness differences in MIDAS are less than the axial resolution of ultrasound equipment, and therefore the analyses may overstate the ability of these instruments to determine the fine differences reported. The differences presented were calculated, not measured, by comparing within-group or between-group intimal-medial thickness data. That it is not possible to directly measure these differences does not affect the validity or appropriateness of determining their presence or use in analyses of grouped data. The comments by Dr Abt concerning the statistical significance (or lack thereof) of the difference in cardiovascular events between patients treated with hydrochlorothiazide and isradipine in the MIDAS trial seem http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)-Reply

Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/the-multicenter-isradipine-diuretic-atherosclerosis-study-midas-reply-Ufcqtxeu70

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1997 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1997.03540280035026
Publisher site
See Article on Publisher Site

Abstract

In Reply. —Regarding the comments by Dr Kaufman on the ultrasound data, the ultrasound instrument used in MIDAS was Biosound 2000 II spectrum analysis with 8-MHz annular arrays (approximate axial resolution, 0.3 mm). This was defined in the original protocol and previously published.1 Kaufman notes that the intimal-medial thickness differences in MIDAS are less than the axial resolution of ultrasound equipment, and therefore the analyses may overstate the ability of these instruments to determine the fine differences reported. The differences presented were calculated, not measured, by comparing within-group or between-group intimal-medial thickness data. That it is not possible to directly measure these differences does not affect the validity or appropriateness of determining their presence or use in analyses of grouped data. The comments by Dr Abt concerning the statistical significance (or lack thereof) of the difference in cardiovascular events between patients treated with hydrochlorothiazide and isradipine in the MIDAS trial seem

Journal

JAMA – American Medical Association

Published: Jan 22, 1997

There are no references for this article.